Comparing of Loxo Oncology Inc. (LOXO) and Neuralstem Inc. (NASDAQ:CUR)

Loxo Oncology Inc. (NASDAQ:LOXO) and Neuralstem Inc. (NASDAQ:CUR), both competing one another are Biotechnology companies. We will compare their risk, analyst recommendations, profitability, dividends, institutional ownership, earnings and valuation.

Earnings and Valuation Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Loxo Oncology Inc. 144.80M 49.82 62.98M -2.08 0.00 Neuralstem Inc. N/A 15.75 7.92M -0.52 0.00 We can see in table 1 the earnings per share (EPS), gross revenue and valuation of Loxo Oncology Inc. and Neuralstem Inc.


Table 2 shows us the return on assets, return on equity and net margins of both companies. Net Margins Return on Equity Return on Assets Loxo Oncology Inc. -43.49% -16.4% -8.7% Neuralstem Inc. 0.00% -123.1% -74.7% Volatility and Risk

Loxo Oncology Inc. is 122.00% more volatile than Standard & Poor’s 500 because the company has a beta of 2.22. Neuralstem Inc.’s 84.00% more volatile than Standard & Poor’s 500 volatility due to the company’s 1.84 beta.


The Current Ratio of Loxo Oncology Inc. is 3.6 while its Quick Ratio stands at 3.6. The Current Ratio of rival Neuralstem Inc. is 5.5 and its Quick Ratio is has 5.5. Neuralstem Inc. is better equipped to clear short and long-term obligations than Loxo Oncology Inc.

Analyst Recommendations

The table delivered features the ratings and recommendations for Loxo Oncology Inc. and Neuralstem Inc.

Loxo Oncology Inc. has an average price target of $207.67, and a -11.47% downside potential.

Institutional & Insider Ownership

Loxo Oncology Inc. and Neuralstem Inc. has shares owned by institutional investors as follows: 99.2% and 6.3%. Insiders owned roughly 7.3% of Loxo Oncology Inc.’s shares. Competitively, insiders own roughly 0.3% of Neuralstem Inc.’s shares.


In this table we provide the Week, Month, Quarter, Half Year, Year and YTD Performance of both pretenders. Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD) Loxo Oncology Inc. -3.59% -23.23% -18.07% -24.66% 70.01% 60.82% Neuralstem Inc. -14.71% -24.96% -62.7% -74.46% -80.85% -75.06% For the past year Loxo Oncology Inc. had bullish trend while Neuralstem Inc. had bearish trend.


Loxo Oncology Inc. beats Neuralstem Inc. on 6 of the 10 factors.

Loxo Oncology, Inc., a biopharmaceutical company, develops and sells medicines for patients with genetically defined cancers in the United States. Its lead product candidate comprises larotrectinib, an oral selective inhibitor of tropomyosin receptor kinase (TRK), which is in adult Phase 1 trial, a pediatric Phase 1/2 trial, and an adult/adolescent Phase 2 trial for the treatment of patients with tumor types, such as lung, head and neck, melanoma, colorectal, sarcoma, and breast cancer. The companyÂ’s preclinical programs include LOXO-195, a drug candidate in preclinical development to address predicted acquired resistance mechanisms; RET inhibitor that optimizes potency for rearranged during transfection (RET) fusion proteins, mutations, and anticipated mechanisms of acquired resistance; and FGFR inhibitor that enables potently inhibiting FGFR isoforms comprising four isoforms with tyrosine kinase domains. It has a drug discovery collaboration agreement with Array BioPharma, Inc. to obtain various rights to TRK inhibitor program and oncology targets. Loxo Oncology, Inc. was founded in 2013 and is headquartered in Stamford, Connecticut.

Neuralstem, Inc., a clinical stage biopharmaceutical company, focuses on the research and development of nervous system therapies based on its proprietary human neuronal stem cells and small molecule compounds. The companyÂ’s stem cell based technology enables the isolation and expansion of human neural stem cells from various areas of the developing human brain and spinal cord enabling the generation of physiologically relevant human neurons of various types. It is developing products include NSI-189, a chemical entity, which is in Phase II clinical trial for the treatment of major depressive disorder, as well as is in preclinical programs for the MCAO stroke, type 1 and 2 diabetes related neuropathy, irradiation-induced cognition, long-term potentiation enhancement, and angelman syndrome. The company is also developing NSI-566, which has completed Phase II clinical trial for treating amyotrophic lateral sclerosis disease, as well as is in Phase I clinical trials for the treatment of chronic spinal cord injury and motor deficits due to ischemic stroke. Neuralstem, Inc. was founded in 1996 and is headquartered in Germantown, Maryland.

Click Here to Continue...

Add a Comment

Your email address will not be published. Required fields are marked *